Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

  • End date
    May 14, 2023
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 14 May 2022
graft versus host disease
hodgkin's disease
ejection fraction
measurable disease
growth factor
neutrophil count
blood transfusion
diffuse large b-cell lymphoma
b-cell lymphoma
mantle cell lymphoma
line of therapy
large b-cell lymphoma


The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.

Condition Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Treatment Ibrutinib, Abexinostat
Clinical Study IdentifierNCT03939182
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on14 May 2022


Yes No Not Sure

Inclusion Criteria

Patient is ≥ 18 years of age at the time of signing Informed Consent
Patient is able and willing to adhere to the study visit schedule and other protocol requirements
Patient has histologically confirmed diagnosis of R/R mantle cell lymphoma or diffuse large B cell lymphoma
Diffuse large B cell lymphoma patients must have received at least 1 prior regimen and received, declined, or is ineligible for autologous or allogeneic stem cell transplant
Diffuse large B cell lymphoma patients must have non-germinal center subtype disease applying the Hans classification algorithm using immunohistochemistry markers CD10, BCL6, and MUM1 (8)
Mantle cell lymphoma patients must have received at least 1 line of therapy
Allogeneic stem cell transplant recipients be greater than 6 months post transplant, not on immunosuppression for prevention of graft versus host disease for >3 months and without active graft versus host disease
Autologous stem cell transplant recipients must have adequate bone marrow recovery and are transfusion independent
Patients with transformed DLBCL from an antecedent or simultaneous indolent B-cell Non-Hodgkin lymphoma are permitted
Patient has at least one measurable lesion (≥ 1.5 cm) according to RECIL
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Patient has adequate bone marrow and organ function by
Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L independent of growth factor support
Platelets ≥100 x 10^9/L independent of transfusion
°For patients with documented bone marrow involvement of underlying MCL or
DLBCL at time of study enrollment, platelets must be ≥75 x 10^9/L independent
of transfusion
Hemoglobin (Hgb) ≥ 9.0 g/dL
°For patients with documented bone marrow involvement of underlying MCL or
DLBCL at time of study enrollment, Hgb must be ≥ 8.0 g/dL
International Normalized Ratio (INR) ≤ 1.5
Creatinine clearance > 25 mL/min as determined by the Cockcroft-Gault equation or a 24-hour urine collection
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ ULN (or ≤3 x ULN if liver involved with disease Total serum bilirubin ≤ 1.5 ULN unless bilirubin rise is due to Gilbert"s syndrome or of non-hepatic origin
Normal serum potassium level with or without supplementation
Left Ventricular Ejection Fraction (LVEF) ≥ 50%
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trial. For females, these restrictions apply for 30 days month after the last dose of study drug. For males, these restrictions apply for 120 days after the last dose of study drug. Refer to section 9.7 "Reproductive toxicity" for additional details
Women of childbearing potential must have a negative urine pregnancy test at Screening and within 7 days of treatment initiation
Men must agree to not donate sperm during and 12 months after the study. Women should not donate ova/ooctyes for the purposes of
Patient is able to swallow and retain oral medications

Exclusion Criteria

Patients previously treated with ibrutinib or HDAC inhibitor
Patient has a history of non-compliance to medical regimen or inability to grant consent
Patient is concurrently using other approved or investigational antineoplastic agent
Patient has not recovered to Grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy
Patient has had major surgery or a wound that has not fully healed within 4 weeks of starting study drugs
Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study
Patient has evidence of active graft versus host disease (GVHD)
Patient has active central nervous system (CNS) disease or meningeal involvement
Patient has history of stroke or intracranial hemorrhage ≤ 6 months from starting study drugs
Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
Patient has clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification, Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO), unstable angina pectoris, symptomatic pericarditis, QTcF > 480 msec on the screening ECG (using the QTcF formula), or history of congenital long QT syndrome
Patient has a concurrent active malignancy
Malignancies treated with a curative intent with an expected life expectancy ≥ 5 years or a non-competing life expectancy risk are eligible (i.e. adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer, early stage breast cancer, treated prostate cancer or any other cancer from which the patient has been disease free for ≥ 3 years)
Patient with known history of human immunodeficiency virus (HIV), or any uncontrolled active systemic infection
Patients with acute viral hepatitis or a history of chronic or active HBV or HCV infection
Hepatisis B surface antigen and core antibody testing are required at screening. If Hepatisis B surface antigen is positive then HBV PCR is required and if positive, then patient will be excluded
Patient has hepatic failure (Child-Pugh Class C)
Patient is currently receiving increasing or chronic treatment (> 10 days) with corticosteroids or another immunosuppressive agent. Patients requiring chronic therapy with steroids may take no more than 10mg daily of prednisone or equivalent
Hepatisis C antibody testing is required at screening. If positive, Hepatisis C PCR is required and if positive, pHepatisis C PCR is required and if positive, then patient will be excluded
Patient requires chronic treatment with a strong cytochrome P450 (CYP) 3A4 inhibitors, and inducers, or drugs known to induce Torsades de Pointes and the treatment cannot be discontinued or switched to a different medication prior to starting study drug (Appendix 1 and 3)
Patients with known bleeding diathesis (e.g. von Willebrand "s disease) or hemophilia
Patient is currently receiving warfarin or other Vitamin K antagonist. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed. Refer to Section 9.5 for Concomitant medication
Vaccinated with live, attenuated vaccines within 4 weeks of randomization
Patients with any life-threatening illness, medical condition or organ system dysfunction that in the opinion of the investigator could compromise the subject"s safety, interfere with absorption of metabolism of study drugs or put the study outcomes at undue risk
Women who are pregnant or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note